市場調查報告書

非侵入性產前檢查(NIPT):全球市場的展望(2018年∼2027年)

Non-Invasive Prenatal Testing - Global Market Outlook (2018-2027)

出版商 Stratistics Market Research Consulting 商品編碼 939023
出版日期 內容資訊 英文 198 Pages
商品交期: 2-3個工作天內
價格
非侵入性產前檢查(NIPT):全球市場的展望(2018年∼2027年) Non-Invasive Prenatal Testing - Global Market Outlook (2018-2027)
出版日期: 2020年04月01日內容資訊: 英文 198 Pages
簡介

全球非侵入性產前檢查(NIPT)市場,2018年是34億3,000萬美金。該市場,預計在預測期間內以14.5%的年複合成長率成長,2027年達到116億2,000萬美元。促進市場成長的主要原因,是NIPT的認識相關計劃的增加和孕產婦的增加。但,缺乏有能力的專家是抑制市場成長的要素。

本報告提供全球非侵入性產前檢查市場的相關調查,市場機會和趨勢,成長及阻礙因素,各手法、產品、妊娠期間與風險類型、檢驗類型、最終用途、地區的市場分析,競爭情形,主要企業的簡介等的資訊。

目錄

第1章 摘要整理

第2章 簡介

第3章 市場趨勢分析

  • 簡介
  • 成長要素
  • 阻礙因素
  • 市場機會
  • 威脅
  • 產品分析
  • 終端用戶分析
  • 新興市場
  • 新型冠狀病毒感染疾病的影響

第4章 波特的五力分析

第5章 全球市場:各方法

  • 簡介
  • 微缺失症候群
  • 三體性
    • 巴陶氏症(13三體性)
    • 唐氏症(21三體性)
    • 艾德華茲症候群(18三體性)
  • 透納氏症
  • 母體血漿檢驗的無細胞DNA
  • 生物化學的篩檢試驗
  • 性染色體障礙
  • 超音波篩檢
  • 母體血液檢驗的胎兒細胞
  • 其他方法
    • 囊狀纖維化症
    • 性別決策

第6章 全球市場:各產品

  • 簡介
  • 消耗品
    • 化驗套件、試劑
    • 拋棄式
  • 設備
    • 聚合酵素鏈鎖反應設備
    • NT超音波設備
    • 全基因序列(WGS)
    • 次世代定序系統
    • 微陣列
    • 其他
  • 服務
  • 軟體

第7章 全球市場:各妊娠期間

  • 簡介
  • 25∼36週
  • 0∼12週
  • 13∼24週

第8章 全球市場:各風險類型

  • 簡介
  • 低風險
  • 高風險與平均風險

第9章 全球市場:各檢驗類型

  • 簡介
  • 驗證檢查
  • MaterniT21 PLUS檢驗
  • NIFTY檢驗
  • 產前遺傳檢測
  • 產前檢查
  • 全景檢驗
  • 序列檢查
  • IONA檢驗

第10章 全球市場:終端用戶

  • 簡介
  • 醫院
  • 診斷研究所
  • 學術調查機關

第11章 全球市場: 各地區

  • 簡介
  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 中東、非洲

第12章 主要發展

  • 契約,聯盟,合作,合資企業
  • 收購與合併
  • 新產品的銷售
  • 擴張
  • 其他主要策略

第13章 企業簡介

  • Illumina Inc
  • Thermo Fisher Scientific Inc
  • GE Healthcare
  • Perkinelmer Inc
  • Agilent Technologies Inc
  • Beijing Genomics Institute
  • F. Hoffman-La Roche Ltd
  • Laboratory Corporation of America Holdings
  • Natera Inc
  • Yourgene Health
  • Quest Diagnostics
  • Sequenom
  • Bioarray S.L
  • Berry Genomics
  • LifeCodexx AG
目錄

According to Stratistics MRC, the Global Non-Invasive Prenatal Testing market is accounted for $3.43 billion in 2018 and is expected to reach $11.62 billion by 2027 growing at a CAGR of 14.5% during the forecast period. Some of the key factors such as increasing programs related to awareness and growing maternal period are driving the market growth. However, lack of capable professionals is the restraining factor for the growth of the market.

Non-invasive prenatal testing is as well known as non-invasive parenteral screening, which is a hopeful genetic method of investigative a fetal cell free DNA there in the mothers blood serum for detecting general fetal aneuploidies. Its most important purpose is early recognition of genetic disorders such as trisomy 18 (Edward syndrome), trisomy 21 (Down syndrome), and monosomy X (Turner syndrome). It can as well distinguish the blood group and rhesus actor of the fetus.

By method, down syndrome (Trisomy 21) segment is likely to have a huge demand as it includes positive birth defects, education problems, and facial description. A child with Down syndrome can also contain heart defects and trouble with vision and hearing. According to the centres for illness control and prevention, it is the mostly general chromosomal situation diagnosed in United States. Every year, about six thousands babies born in the United States have Down syndrome. This way that Down syndrome occurs in about one out of each seven hundred babies. On the basis of geography, North America is going to have a lucrative growth during the forecast period due to favourable compensation policies and rise in the occurrence of genetic disorders. This will enlarge the acceptance and command for tests in this region.

Some of the key players in Non-Invasive Prenatal Testing Market include Illumina, Inc , Thermo Fisher Scientific, Inc, GE Healthcare, Perkinelmer Inc, Agilent Technologies, Inc, Beijing Genomics Institute, F. Hoffman-La Roche Ltd., and Laboratory Corporation of America Holdings, Natera, Inc, Yourgene Health, Quest Diagnostics, Sequenom, Bioarray S.L, Berry Genomics and LifeCodexx AG.

Methods Covered:

  • Microdeletion Syndrome
  • Trisomy
  • Turner Syndrome
  • Cell-Free DNA in Maternal Plasma Tests
  • Biochemical Screening Tests
  • Sex Chromosomes Disorders
  • Ultrasound Screening
  • Fetal Cells in Maternal Blood Tests
  • Other Methods

Products Covered:

  • Consumables
  • Instruments
  • Services
  • Software

Gestation Periods Covered:

  • 25-36 weeks
  • 0-12 weeks
  • 13-24 weeks

Risk-Types Covered:

  • Low Risk
  • High & Average Risk

Test Types Covered:

  • Verifi Test
  • MaterniT21 PLUS Test
  • NIFTY Test
  • Harmony Test
  • PrenaTest
  • Panorama Test
  • Sequenom Test
  • IONA Test
  • Bambni Test

End Users Covered:

  • Hospitals
  • Diagnostic Laboratories
  • Academic and Research Institutes

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • Italy
    • UK
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2017, 2018, 2019, 2023 and 2027
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic analysis: Drivers and Constraints, Product/Technology Analysis, Porter's five forces analysis, SWOT analysis, etc.
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking

Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Non-Invasive Prenatal Testing Market, By Method

  • 5.1 Introduction
  • 5.2 Microdeletion Syndrome
  • 5.3 Trisomy
    • 5.3.1 Patau Syndrome (Trisomy 13)
    • 5.3.2 Down Syndrome (Trisomy 21)
    • 5.3.3 Edwards Syndrome (Trisomy 18)
  • 5.4 Turner Syndrome
  • 5.5 Cell-Free DNA in Maternal Plasma Tests
  • 5.6 Biochemical Screening Tests
  • 5.7 Sex Chromosomes Disorders
  • 5.8 Ultrasound Screening
  • 5.9 Fetal Cells in Maternal Blood Tests
  • 5.10 Other Methods
    • 5.10.1 Cystic Fibrosis
    • 5.10.2 Sex Determination

6 Global Non-Invasive Prenatal Testing Market, By Product

  • 6.1 Introduction
  • 6.2 Consumables
    • 6.2.1 Assay Kits & Reagents
    • 6.2.2 Disposables
  • 6.3 Instruments
    • 6.3.1 Polymerase Chain Reaction Instruments
    • 6.3.2 Nuchal Translucency Ultrasound Devices
    • 6.3.3 Whole Genome Sequencing (WGS)
    • 6.3.4 Next-Generation Sequencing Systems
    • 6.3.5 Microarrays
    • 6.3.6 Other Instruments
      • 6.3.6.1 Microscopes
      • 6.3.6.2 Centrifuges
      • 6.3.6.3 Incubators
      • 6.3.6.4 UV Systems
  • 6.4 Services
  • 6.5 Software

7 Global Non-Invasive Prenatal Testing Market, By Gestation Period

  • 7.1 Introduction
  • 7.2 25-36 weeks
  • 7.3 0-12 weeks
  • 7.4 13-24 weeks

8 Global Non-Invasive Prenatal Testing Market, By Risk-Type

  • 8.1 Introduction
  • 8.2 Low Risk
  • 8.3 High & Average Risk

9 Global Non-Invasive Prenatal Testing Market, By Test Type

  • 9.1 Introduction
  • 9.2 Verifi Test
  • 9.3 MaterniT21 PLUS Test
  • 9.4 NIFTY Test
  • 9.5 Harmony Test
  • 9.6 PrenaTest
  • 9.7 Panorama Test
  • 9.8 Sequenom Test
  • 9.9 IONA Test
  • 9.10 Bambni Test

10 Global Non-Invasive Prenatal Testing Market, By End User

  • 10.1 Introduction
  • 10.2 Hospitals
  • 10.3 Diagnostic Laboratories
  • 10.4 Academic and Research Institutes

11 Global Non-Invasive Prenatal Testing Market, By Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 New Zealand
    • 11.4.6 South Korea
    • 11.4.7 Rest of Asia Pacific
  • 11.5 South America
    • 11.5.1 Argentina
    • 11.5.2 Brazil
    • 11.5.3 Chile
    • 11.5.4 Rest of South America
  • 11.6 Middle East & Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 UAE
    • 11.6.3 Qatar
    • 11.6.4 South Africa
    • 11.6.5 Rest of Middle East & Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 Illumina Inc
  • 13.2 Thermo Fisher Scientific Inc
  • 13.3 GE Healthcare
  • 13.4 Perkinelmer Inc
  • 13.5 Agilent Technologies Inc
  • 13.6 Beijing Genomics Institute
  • 13.7 F. Hoffman-La Roche Ltd
  • 13.8 Laboratory Corporation of America Holdings
  • 13.9 Natera Inc
  • 13.10 Yourgene Health
  • 13.11 Quest Diagnostics
  • 13.12 Sequenom
  • 13.13 Bioarray S.L
  • 13.14 Berry Genomics
  • 13.15 LifeCodexx AG

List of Tables

  • Table 1 Global Non-Invasive Prenatal Testing Market Outlook, By Region (2017-2027) ($MN)
  • Table 2 Global Non-Invasive Prenatal Testing Market Outlook, By Method (2017-2027) ($MN)
  • Table 3 Global Non-Invasive Prenatal Testing Market Outlook, By Microdeletion Syndrome (2017-2027) ($MN)
  • Table 4 Global Non-Invasive Prenatal Testing Market Outlook, By Trisomy (2017-2027) ($MN)
  • Table 5 Global Non-Invasive Prenatal Testing Market Outlook, By Patau Syndrome (Trisomy 13) (2017-2027) ($MN)
  • Table 6 Global Non-Invasive Prenatal Testing Market Outlook, By Down Syndrome (Trisomy 21) (2017-2027) ($MN)
  • Table 7 Global Non-Invasive Prenatal Testing Market Outlook, By Edwards Syndrome (Trisomy 18) (2017-2027) ($MN)
  • Table 8 Global Non-Invasive Prenatal Testing Market Outlook, By Turner Syndrome (2017-2027) ($MN)
  • Table 9 Global Non-Invasive Prenatal Testing Market Outlook, By Cell-Free DNA in Maternal Plasma Tests (2017-2027) ($MN)
  • Table 10 Global Non-Invasive Prenatal Testing Market Outlook, By Biochemical Screening Tests (2017-2027) ($MN)
  • Table 11 Global Non-Invasive Prenatal Testing Market Outlook, By Sex Chromosomes Disorders (2017-2027) ($MN)
  • Table 12 Global Non-Invasive Prenatal Testing Market Outlook, By Ultrasound Screening (2017-2027) ($MN)
  • Table 13 Global Non-Invasive Prenatal Testing Market Outlook, By Fetal Cells in Maternal Blood Tests (2017-2027) ($MN)
  • Table 14 Global Non-Invasive Prenatal Testing Market Outlook, By Other Methods (2017-2027) ($MN)
  • Table 15 Global Non-Invasive Prenatal Testing Market Outlook, By Cystic Fibrosis (2017-2027) ($MN)
  • Table 16 Global Non-Invasive Prenatal Testing Market Outlook, By Sex Determination (2017-2027) ($MN)
  • Table 17 Global Non-Invasive Prenatal Testing Market Outlook, By Product (2017-2027) ($MN)
  • Table 18 Global Non-Invasive Prenatal Testing Market Outlook, By Consumables (2017-2027) ($MN)
  • Table 19 Global Non-Invasive Prenatal Testing Market Outlook, By Assay Kits & Reagents (2017-2027) ($MN)
  • Table 20 Global Non-Invasive Prenatal Testing Market Outlook, By Disposables (2017-2027) ($MN)
  • Table 21 Global Non-Invasive Prenatal Testing Market Outlook, By Instruments (2017-2027) ($MN)
  • Table 22 Global Non-Invasive Prenatal Testing Market Outlook, By Polymerase Chain Reaction Instruments (2017-2027) ($MN)
  • Table 23 Global Non-Invasive Prenatal Testing Market Outlook, By Nuchal Translucency Ultrasound Devices (2017-2027) ($MN)
  • Table 24 Global Non-Invasive Prenatal Testing Market Outlook, By Whole Genome Sequencing (WGS) (2017-2027) ($MN)
  • Table 25 Global Non-Invasive Prenatal Testing Market Outlook, By Next-Generation Sequencing Systems (2017-2027) ($MN)
  • Table 26 Global Non-Invasive Prenatal Testing Market Outlook, By Microarrays (2017-2027) ($MN)
  • Table 27 Global Non-Invasive Prenatal Testing Market Outlook, By Other Instruments (2017-2027) ($MN)
  • Table 28 Global Non-Invasive Prenatal Testing Market Outlook, By Services (2017-2027) ($MN)
  • Table 29 Global Non-Invasive Prenatal Testing Market Outlook, By Software (2017-2027) ($MN)
  • Table 30 Global Non-Invasive Prenatal Testing Market Outlook, By Gestation Period (2017-2027) ($MN)
  • Table 31 Global Non-Invasive Prenatal Testing Market Outlook, By 25-36 weeks (2017-2027) ($MN)
  • Table 32 Global Non-Invasive Prenatal Testing Market Outlook, By 0-12 weeks (2017-2027) ($MN)
  • Table 33 Global Non-Invasive Prenatal Testing Market Outlook, By 13-24 weeks (2017-2027) ($MN)
  • Table 34 Global Non-Invasive Prenatal Testing Market Outlook, By Risk-Type (2017-2027) ($MN)
  • Table 35 Global Non-Invasive Prenatal Testing Market Outlook, By Low Risk (2017-2027) ($MN)
  • Table 36 Global Non-Invasive Prenatal Testing Market Outlook, By High & Average Risk (2017-2027) ($MN)
  • Table 37 Global Non-Invasive Prenatal Testing Market Outlook, By Test Type (2017-2027) ($MN)
  • Table 38 Global Non-Invasive Prenatal Testing Market Outlook, By Verifi Test (2017-2027) ($MN)
  • Table 39 Global Non-Invasive Prenatal Testing Market Outlook, By MaterniT21 PLUS Test (2017-2027) ($MN)
  • Table 40 Global Non-Invasive Prenatal Testing Market Outlook, By NIFTY Test (2017-2027) ($MN)
  • Table 41 Global Non-Invasive Prenatal Testing Market Outlook, By Harmony Test (2017-2027) ($MN)
  • Table 42 Global Non-Invasive Prenatal Testing Market Outlook, By PrenaTest (2017-2027) ($MN)
  • Table 43 Global Non-Invasive Prenatal Testing Market Outlook, By Panorama Test (2017-2027) ($MN)
  • Table 44 Global Non-Invasive Prenatal Testing Market Outlook, By Sequenom Test (2017-2027) ($MN)
  • Table 45 Global Non-Invasive Prenatal Testing Market Outlook, By IONA Test (2017-2027) ($MN)
  • Table 46 Global Non-Invasive Prenatal Testing Market Outlook, By Bambni Test (2017-2027) ($MN)
  • Table 47 Global Non-Invasive Prenatal Testing Market Outlook, By End User (2017-2027) ($MN)
  • Table 48 Global Non-Invasive Prenatal Testing Market Outlook, By Hospitals (2017-2027) ($MN)
  • Table 49 Global Non-Invasive Prenatal Testing Market Outlook, By Diagnostic Laboratories (2017-2027) ($MN)
  • Table 50 Global Non-Invasive Prenatal Testing Market Outlook, By Academic and Research Institutes (2017-2027) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.